Table 1.
Characteristics of the entire patient cohort
| Factor | SBRT (N = 99) |
Surgery (N = 106) |
p-value |
|---|---|---|---|
| Age (years) | |||
| Median (range) | 78 (70–88) | 73 (70–83) | 0.001 |
| Gender | |||
| Male | 77 | 61 | 0.001 |
| Female | 22 | 45 | |
| Tumor size (cm) | |||
| Median (range) | 2.2 (1.0–5.0) | 2.0 (1.0–5.0) | 0.621 |
| T stage | |||
| T1 | 83 | 86 | 0.740 |
| T2 | 16 | 20 | |
| Histology | |||
| NSCLC-NOS | 18 | 4 | 0.001 |
| SCC | 32 | 25 | |
| Ade | 35 | 77 | |
| probable | 14 | 0 | |
| FEV1 | |||
| Median (range) | 1.26 (0.38–2.51) | 1.74 (0.78–3.04) | 0.001 |
| FEV1/FVC (%) | |||
| Median (range) | 91 (38–129) | 107 (54–126) | 0.001 |
| CCI (%) | |||
| 0 | 45 (46) | 77 (73) | 0.001 |
| 1–2 | 48 (48) | 25 (24) | |
| ≥ 3 | 6 (6) | 4 (2) | |
| KPS | |||
| Median (range) | 90 (60–100) | 90 (80–100) | 0.347 |
| Tumor location | |||
| RUL | 26 | 29 | 0.323 |
| RML | 18 | 16 | |
| RLL | 21 | 20 | |
| LUL | 15 | 26 | |
| LLL | 19 | 15 | |
| SBRT dose | |||
| 50Gy/4fx | 19 | N/A | |
| 50Gy/5fx | 60 | ||
| 50Gy/10fx | 12 | ||
| 60Gy/8fx | 5 | ||
| 70Gy/10fx | 3 | ||
| Operation | |||
| lobectomy | 90 | N/A | |
| sublobar resection | 16 | ||
| VATS | 84 | ||
| thoracotomy | 22 | ||
SBRT stereotactic body radiotherapy, NSCLC non–small cell lung cancer, NOS not otherwise specified, Ade adenocarcinoma, SCC squamous cell carcinoma, FEV1 forced expiratory volume in 1 s, FEV1/FVC% FEV1 to forced vital capacity ratio, CCI Charlson comorbidity index, KPS Karnofsky performance status, fx fractions, RUL right upper lobe, RML right middle lobe, RLL right lower lobe, LUL left upper lobe, LLL left lower lobe, VATS video-assisted thoracic surgery